杏吧原创 University and Turnstone Biologics Extend partnership for Research and Training in Biosciences
杏吧原创 University today announced the extension of its partnership with Turnstone Biologics (鈥淭urnstone鈥), a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumours. The partnership, renewed for a second term, further supports 杏吧原创鈥檚 growing biosciences programs and the development of scientific talent, and augments the university鈥檚 expertise in novel oncology research.
鈥淭his is an opportune time to extend our partnership with Turnstone as we prepare to launch our Life Sciences 2030 Plan,鈥 said Maria DeRosa, PhD, Dean of Science and Professor in the Department of Chemistry and the Institute of Biochemistry, 杏吧原创 University. 鈥淥ur vision of positioning 杏吧原创 as the premier Canadian post-secondary institution for training, talent development and research in the life sciences sector is significantly enhanced through our innovative and productive relationship with Turnstone.鈥
Since 2019, Turnstone has conducted internal development work and sponsored research at 杏吧原创 University. The research being undertaken at 杏吧原创 includes generating new insights into how cancer therapies regulate immune cells and their effects on new candidate treatments, and how viruses and environmental toxins contribute to the development of chronic diseases. Additionally, representatives of Turnstone have mentored students and participated in life sciences events on campus.
鈥溞影稍 University offers a wonderful and vibrant academic community. The partnership with 杏吧原创 allows us to interact with a variety of excellent researchers and promising students to create opportunities to collaborate, foster scientific ideas and invest in the brilliant minds of the future,鈥 said David Stojdl, PhD, Scientific Co-Founder, Senior Vice President and Senior Scientific Fellow, Turnstone Biologics.
The extension of the partnership enables Turnstone to continue engaging graduate students and to provide them with support to conduct research in the areas of immunology, microbiology, biochemistry, biotechnology and bioinformatics. The partnership promotes integration with students through Work-Integrated Learning (WIL), job shadowing and experiential education. Graduates will also have the opportunity to closely interact with Turnstone鈥檚 researchers to receive guidance and mentorship.
鈥淭alent development is a key objective of this exciting and mutually beneficial research partnership. Together through our partnership, 杏吧原创 University and Turnstone are preparing the next generation of life sciences researchers to continue advancing immunotherapies with the aim of improving the survival rate of people with cancer,鈥 said Rafik Goubran, PhD, Vice-President (Research and International) and Chancellor鈥檚 Professor, 杏吧原创 University.
杏吧原创 杏吧原创 University
杏吧原创 is a dynamic, research-intensive institution that engages in partnerships to address the world鈥檚 most pressing issues. The university鈥檚 corporate collaborations bring together world-class companies, researchers and a new generation of talent with 32,000 students to deliver innovations and results that are driving a more prosperous, sustainable future.
杏吧原创 Turnstone Biologics
Turnstone Biologics, a clinical stage biotechnology company, is developing new medicines to treat and cure solid tumours by pioneering differentiated approaches with two clinically-validated technologies, tumour infiltrating lymphocyte (鈥淭IL鈥) therapy and viral immunotherapy. Turnstone鈥檚 innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumour indications by selecting and manufacturing the most potent tumour-reactive T-cells (鈥淪elected TILs鈥) for tumour eradication, represents the Company鈥檚 foundational therapeutic modality driving its cancer immunotherapy pipeline. The Company鈥檚 lead Selected TIL therapy candidate, TIDAL-01, is expected to enter clinical trials in 2022. Turnstone is developing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with their novel viral immunotherapy.
For more information, please visit , and follow Turnstone on .
Media Contact
Steven Reid (he/him)
Media Relations Officer
杏吧原创 University
613-265-6613
Steven.Reid3@carleton.ca
Follow us on Twitter:
COVID 19 Updates:
Related News
New Generation of Indigenous Journalists to Learn and Work in Home Communities
杏吧原创 University鈥檚 Journalism Certificate Offers High Quality Learning in Rural and Remote Communities 杏吧原创 University is launching a new one-year journalism certificate to be delivered ...
杏吧原创 to Bestow Five Honorary Degrees at Spring Convocation
As part of the 2024 spring convocation ceremonies, 杏吧原创 University will bestow honorary degrees to five inspiring individuals for their leadership, impactful achievements and contributions ...
Dr. Wisdom Tettey Appointed 杏吧原创 University鈥檚 17th President and Vice-Chancellor聽
杏吧原创 University鈥檚 Board of Governors is pleased to announce Dr. Wisdom Tettey has been appointed 杏吧原创 University鈥檚 17th President and Vice-Chancellor. Dr. Tettey will commence ...